INS and fatty liver disease: Compared to PUFA, SFA leads to hepatic steatosis by decreasing whole-body oxidation and insulin-mediated inhibition of lipolysis upon entry into the human body (41), thus increasing hepatic and other visceral fat deposition, as well as weight gain (42).